Ratings TruBridge, Inc.

Equities

TBRG

US2053061030

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-06 pm EDT			5-day change	1st Jan Change
8.11 ^USD	-4.92%		-2.64%	-27.59%

Apr. 23	TruBridge Raises Threshold Triggering Shareholder Rights Plan to 15%	MT
Apr. 01	TruBridge, Inc. Appoints Vita Macintyre as Principal Accounting Officer	CI

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.
The company has a poor ESG score according to Refinitiv, which ranks companies by sector.

Strengths

The stock, which is currently worth 2024 to 0.32 times its sales, is clearly overvalued in comparison with peers.
The company appears to be poorly valued given its net asset value.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analyst opinion has improved significantly over the past four months.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
TRUBRIDGE, INC.	-27.59%	116M		C-
VEEVA SYSTEMS INC.	+5.52%	32.83B		C
PRO MEDICUS LIMITED	+18.02%	7.73B		C-
SECTRA AB	+24.04%	3.96B		B-
EVOLENT HEALTH, INC.	-17.53%	3.12B		C-
OMNICELL, INC.	-20.33%	1.38B		B
LUNIT INC.	-30.65%	1.2B		-
SIMULATIONS PLUS, INC.	+7.73%	963M		C
B-SOFT CO.,LTD.	-33.44%	934M		-
VERADIGM INC.	-26.60%	829M	-	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes